Muutke küpsiste eelistusi

Statins: The HMG CoA reductase inhibitors in perspective 2nd edition [Kõva köide]

3.00/5 (1 hinnangut Goodreads-ist)
Edited by , Edited by , Edited by
  • Formaat: Hardback, 262 pages, kõrgus x laius: 246x189 mm, kaal: 916 g, 20 Tables, black and white
  • Ilmumisaeg: 04-Dec-2003
  • Kirjastus: CRC Press
  • ISBN-10: 1841842923
  • ISBN-13: 9781841842929
Teised raamatud teemal:
Statins: The HMG CoA reductase inhibitors in perspective 2nd editionSuurem pilt
  • Formaat: Hardback, 262 pages, kõrgus x laius: 246x189 mm, kaal: 916 g, 20 Tables, black and white
  • Ilmumisaeg: 04-Dec-2003
  • Kirjastus: CRC Press
  • ISBN-10: 1841842923
  • ISBN-13: 9781841842929
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9781841842929.html
Märksõnad:
What is a statin? It is the most powerful lipid-lowering agent yet produced. Its main action is to lower the low-density lipoprotein (LDL) cholesterol level, thereby reducing the overall cholesterol level in the blood. In this new edition of this popular book, the authors examine the existing and emerging statins and their beneficial effectiveness in reducing serum cholesterol. New chapters cover combination therapy in lipid-lowering, new 'Megatrials' (HPS and PPP) and the PROSPER study. Also presented are the effects of statins on non-vascular conditions such as osteoporosis, cancer, dementia and diabetes.
Contributors vii
Preface to the first edition ix
Preface to the second edition x
Hyperlipidaemia as a risk factor for vascular heart disease
1(18)
Allan Gaw
Lipid control in the pre-statin era
19(13)
William B Kannel
Peter WF Wilson
The discovery and development of the statins
32(13)
Akira Endo
Comparative chemistry, pharmacology and mechanism of action of the statins
45(13)
Allan Gaw
Christopher J Packard
Ancillary benefits of the statins
58(15)
Brendan M Buckley
Angiographic and IVUS techniques evaluating progression and regression of coronary atherosclerosis: statin intervention trials in perspective
73(23)
Philippine Kies
Albert VG Bruschke
J Wouter Jukema
The Scandinavian Simvastatin Survival Study (4S)
96(14)
Ole Faergeman
Primary prevention of coronary heart disease with statins
110(13)
James Shepherd
The CARE trial: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
123(21)
J Wayne Warnica
The LIPID study: results and implications for clinical practice
144(8)
Andrew M Tonkin
Mega-trials: the Prospective Pravastatin Pooling Project (PPP) and the Heart Protection Study (HPS)
152(23)
Robert P Byington
Curt D Furberg
The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
175(14)
James Shepherd
Gerard Jan Blauw
Michael B Murphy
Allan Gaw
Combination therapy with statins
189(11)
Gilbert R Thompson
Guidelines for clinical use of the statins
200(13)
Christopher J Packard
The cost-effectiveness of statin use
213(15)
J Jaime Caro
Krista F Huybrechts
Unanswered questions about the use of statins
228(13)
Mehmet Cilingiroglu
Christie M Ballantyne
Statin therapy for the 21st century
241(12)
James Shepherd
Index 253


Allan Gaw MD PhD, Christopher J. Packard MRCPath DSc, James hepherd MB ChB PhD FRCPath FRCP(Glasg),